Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia
13
Zitationen
15
Autoren
2017
Jahr
Abstract
To our knowledge, our findings are the first data reporting on epoetin versus darbepoetin use for CIA and support recently concluded lawsuits involving allegations of illegal marketing practices of the manufacturer of darbepoetin.
Ähnliche Arbeiten
The Ferric Reducing Ability of Plasma (FRAP) as a Measure of “Antioxidant Power”: The FRAP Assay
1996 · 22.044 Zit.
Anemia of Chronic Disease
2005 · 3.699 Zit.
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
2006 · 2.732 Zit.
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 · 2.169 Zit.
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
2006 · 2.088 Zit.